Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab

Cytometry A. 2019 Oct;95(10):1053-1065. doi: 10.1002/cyto.a.23873. Epub 2019 Aug 12.

Abstract

We report the development and validation of a 12 parameter immunofluorescence flow cytometry method for the sensitive determination of cell concentrations, their expression of PD-1, and PD-1 receptor occupancy. Cell subsets include CD4+ and CD8+ -T-cells, B-cells, natural killer cells, classical-, intermediate- and non-classical monocytes, and myeloid- and plasmacytoid dendritic cells. Cells were isolated from peripheral blood by density gradient centrifugation. The validation parameters included specificity, linearity, limit of quantification, precision, biological within- and between subject variations. The lower limit of quantification was 5.0% of PD-1+ cells. Samples were stable for at least 153 days of storage at -80°C. The clinical applicability of the method was demonstrated in 11 advanced cancer patients by the successful determination of immune cell concentrations, relative number of PD-1+ immune cells, and number of PD-1 molecules per immune cell. Shortly after infusion of nivolumab, receptor occupancy on CD8+ -T-cells was 98%. Similar values were found predose cycle 2, suggesting receptor occupancy remained high throughout the entire cycle. © 2019 International Society for Advancement of Cytometry.

Keywords: PD-1 receptor occupancy; immune cell subsets; immunotherapy; nivolumab; pembrolizumab; pharmacodynamic.

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / metabolism*
  • B7-H1 Antigen / blood
  • B7-H1 Antigen / metabolism*
  • Biomarkers / metabolism
  • Flow Cytometry / methods*
  • Healthy Volunteers
  • Humans
  • Immunoassay / methods*
  • Leukocytes / metabolism*
  • Nivolumab / administration & dosage
  • Nivolumab / metabolism*
  • Programmed Cell Death 1 Receptor / metabolism*
  • Signal-To-Noise Ratio

Substances

  • Antibodies, Monoclonal, Humanized
  • B7-H1 Antigen
  • Biomarkers
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab